Trial Profile
A real-world study comparing efficacy and safety of tyrosine kinase inhibitors (afatinib, erlotinib, gefitinib) in patients with non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Nov 2017
Price :
$35
*